Protagonist doses first patient in Phase II study of PTG-300
01 Nov 2019 //
CLINICALTRIALSARINA
Protagonist Therapeutics Receives $1.45 Million SBIR Funding for PTG-300
06 Sep 2018 //
PR NEWSWIRE
Protagonist Therapeutics Initiates Phase 1 Study with Oral Peptide PTG-100
06 Jan 2016 //
PR NEWSWIRE